Thermo Fisher Underscores Allergy Test Opportunity With $3.5 Bil. Phadia Deal
This article was originally published in The Gray Sheet
Executive Summary
Thermo Fisher Scientific wants to claim a dominant share of the budding in vitro allergy testing market segment in the U.S. with its planned $3.5 billion acquisition of Swedish firm Phadia, announced May 19.
You may also be interested in...
Thermo Fisher To Dominate Transplant Dx Market With $925 Million One Lambda Purchase
Deal gives Thermo broad access to $480 million global transplant diagnostics market, a segment growing at a mid- to high-single-digit percentage rate.
Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report
A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.
Companion Dx Partnerships, M&A Deals Help Spur IVD Market Growth – PWC Report
A report from PricewaterhouseCoopers suggests the in vitro diagnostics market will see accelerated growth next year due in part to a surge in companion diagnostics partnerships and M&A deals.